Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Guidance and quality standards
Awaiting development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 active)
Skip to results
Filter by title or keyword
Filter
Area of interest
Area of interest
COVID-19 (9)
Type
(
1 selected
)
Type
Guidance (309)
Quality standard (30)
Guidance programme
Guidance programme
Diagnostics guidance (2)
Health technology evaluations (1)
Highly specialised technologies guidance (1)
Interventional procedures guidance (15)
Medical technologies guidance (7)
Technology appraisal guidance (283)
Apply filters
Showing 31 to 40 of 309
Type: Guidance
Remove Type: Guidance filter
Guidance and quality standards awaiting development
Title
Type
Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer TS ID 11769
Technology appraisal guidance
Benralizumab for previously treated severe nasal polyps [ID1659]
Technology appraisal guidance
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over TS ID 11867
Technology appraisal guidance
Benralizumab with corticosteroids for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis [ID6266]
Technology appraisal guidance
Bentracimab for reversing the antiplatelet activity of ticagrelor TS ID 10550
Technology appraisal guidance
Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]
Technology appraisal guidance
BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]
Technology appraisal guidance
Bimekizumab for treating ankylosing spondylitis TS ID 10334
Technology appraisal guidance
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease TS ID 11991
Technology appraisal guidance
Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa TS ID 10592
Technology appraisal guidance
Previous page
1
2
3
Current page
4
5
6
…
31
Page
4
of
31
Next page
Results per page
10
25
50
All
Back to top